Comparing efficacy and safety of glucagon-like peptide 1 agonist versus sodium-glucose cotransporter 2 (SGLT-2) inhibitors in Chinese patients with type 2 diabetes mellitus Page No: 00

By: Yuanbo Wei, Huihui Ma, Tianshuai Wei

Keywords: Dulaglutide; SGLT-2 inhibitor; Glucagon-like peptide-1; Dapagliflozin; Diabetes mellitus

DOI : 10.36721/PJPS.0000.00.0.REG.000-000.1

Abstract: To compare efficacy and safety of Dula vs. dapagliflozin in Chinese T2DM patients



[View Complete Article]